Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously.
Everyone’s talking about CRISPR-Cas. This biotechnological method offers a relatively quick and easy way to manipulate single genes in cells, meaning they can be precisely deleted, replaced or modified. Furthermore, in recent years, researchers have also been using technologies based on CRISPR-Cas to systematically increase or decrease the activity of individual genes. The corresponding methods have become the worldwide standard within a very short time, both in basic biological research and in applied fields such as plant breeding.
To date, for the most part, researchers could modify only one gene at a time using the method. On occasion, they managed two or three in one go; in one particular case, they were able to edit seven genes simultaneously. Now, Professor Randall Platt and his team at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have developed a process that – as they demonstrated in experiments – can modify 25 target sites within genes in a cell at once. As if that were not enough, this number can be increased still further, to dozens or even hundreds of genes, as Platt points out. At any rate, the method offers enormous potential for biomedical research and biotechnology. “Thanks to this new tool, we and other scientists can now achieve what we could only dream of doing in the past.”
Targeted, large-scale cell reprogramming
Genes and proteins in cells interact in many different ways. The resulting networks comprising dozens of genes ensure an organism’s cellular diversity. For example, they are responsible for differentiating progenitor cells to neuronal cells and immune cells. “Our method enables us, for the first time, to systematically modify entire gene networks in a single step,” Platt says.
Moreover, it paves the way for complex, large-scale cell programming. It can be used to increase the activity of certain genes, while reducing that of others. The timing of this change in activity can also be precisely controlled.
This is of interest for basic research, for example in investigating why various types of cells behave differently or for the study of complex genetic disorders. It will also prove useful for cell replacement therapy, which involves replacing damaged with healthy cells. In this case, researchers can use the method to convert stem cells into differentiated cells, such as neuronal cells or insulin-producing beta cells, or vice versa, to produce stem cells from differentiated skin cells.
The dual function of the Cas enzyme
The CRISPR-Cas method requires an enzyme known as a Cas and a small RNA molecule. Its sequence of nucleobases serves as an “address label”, directing the enzyme with utmost precision to its designated site of action on the chromosomes. ETH scientists have created a plasmid, or a circular DNA molecule, that stores the blueprint of the Cas enzyme and numerous RNA address molecules, arranged in sequences: in other words, a longer address list. In their experiments, the researchers inserted this plasmid into human cells, thereby demonstrating that several genes can be modified and regulated simultaneously.
For the new technique, the scientists did not use the Cas9 enzyme that has featured in most CRISPR-Cas methods to date, but the related Cas12a enzyme. Not only can it edit genes, it can also cut the long “RNA address list” into individual “address labels” at the same time. Furthermore, Cas12a can handle shorter RNA address molecules than Cas9. “The shorter these addressing sequences are, the more of them we can fit onto a plasmid,” Platt says.
Learn more: Revolutionising the CRISPR method
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- 7 CRISPR Stocks for the Future of Medicineon January 15, 2021 at 8:12 pm
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.
- Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?on January 15, 2021 at 12:35 pm
Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report ...
- Scientists Write ‘Hello World’ in Bacterial DNA With Electricity and CRISPRon January 15, 2021 at 4:13 am
A study published on January 11 in the journal Nature Chemical Biology details how the researchers led by Columbia University systems biologist Harris Wang used electricity and the DNA editing tool ...
- CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Nowon January 14, 2021 at 10:27 am
We wrote about CRISPR Therapeutics (CRSP) on January 6 and said traders should "Continue to hold longs risking to $149 now. Our price targets are $200 and $230 for now." CRSP is now trading around ...
- CRISPR gene-editing urgently needs an off-switch – now we have oneon January 13, 2021 at 10:18 am
Making changes to genes with CRISPR has the potential to cure diseases and feed the world, if we can learn to control it. Now it looks like viruses hold the solution ...
- CRISPR and CRISPR-Associated (Cas) Genes Market Significant Demand Foreseen by 2026 | Mirus Bio LLC, Editas Medicine, Takara Bio USAon January 12, 2021 at 2:18 pm
The Study covers exploration of all necessary data related to the Global CRISPR and CRISPR-Associated (Cas) Genes market. All phase of the market is analyzed thoroughly in the Study to provide a ...
- Electricity and CRISPR used to write data to bacterial DNAon January 12, 2021 at 5:55 am
In recent years, researchers have used DNA to encode everything from an operating system to malware. Rather than being a technological curiosity, these efforts were serious attempts to take advantage ...
- With durable monkey data, Verve selects its first CRISPR base editing treatment for human trialson January 12, 2021 at 4:17 am
The company said the treatment removed a cholesterol-associated gene in monkeys, demonstrating durable reductions in LDL “bad” cholestorol.
- CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicineon January 11, 2021 at 7:00 am
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism’s genome, helping to replace the defective genes responsible for a ...
- The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticalson January 11, 2021 at 5:02 am
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...
via Bing News